or ramelteon should be considered for patients primarily suffering from sleep onset insomnia.
The acquisition cost of eszopiclone is comparable to the cost of zolpidem and zaleplon
but much higher than that of older hypnotic agents.
Patients were randomly administered one of three treatments: zaleplon
10 mg, zaleplon
5 mg, and placebo 30 minutes before going to bed.
Blood levels of zaleplon
were measured over 8 hours and confirmed the release of active drug starting 2 hours after ingestion.
is a nonbenzodiazepine receptor agonist approved by the FDA in 1999 for insomnia characterized by difficulty falling asleep.
Premarketing clinical trials found that zaleplon
in short-term use was not associated with any significant adverse effects.
A poster: "Pharmacokinetic Profile of a Modified Release Formulation of Zaleplon
[Sonata] is indicated for sleep initiation, but because of its short half-life it does not improve sleep maintenance.
Eszopiclone (pronounced "es-zoh-PIK-lone") is in the cyclopyrrolone family of drugs and is chemically related to zolpidem (trade name, Ambien), zaleplon
(Sonata), and zoplicone (Imovane).
Established medications for the symptomatic treatment of insomnia include benzodiazepines, zolpidem, zaleplon
, and certain antidepressant or occasionally antihistaminic drugs.
, a new sleep medication recently approved for sale in the United States, appears to be safe and effective for long-term use, Dr.
a private specialty pharmaceutical company, has been granted approximately $245,000 under the Qualifying Therapeutic Discovery Project (QTDP) to help fund clinical trials of SKP-1041, a delayed-release tablet formulation of zaleplon
Findings from a recent meta-analysis suggest that many of the drugs currently available for treating insomnia--including the nonbenzodiazepine hypnotics zolpidem and zaleplon
, some benzodiazepines, and the antidepressant drug trazodone--have not shown consistent effectiveness in improving sleep in older adults (Ann.
, marketed as Sonata by King Pharmaceuticals Inc.
Alexza has combined the technology attributes of the Staccato system with zaleplon
in order to develop a product candidate with a specific profile for middle of the night (MOTN) insomnia.